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LETTERS TO THE EDITOR
Contrast Media: Is There a Preferable Agent
for Coronary Interventions?
The recent article by Grines et al. (1) serves to reawaken the age-old
discussion regarding adverse events, including thrombotic complica-
tions potentially related to contrast media. This phenomenon was
described by Robertson in 1987 (2), when he observed blood clot
formation in angiographic syringes filled with a mixture of contrast
medium and blood that were left stagnant for 30 min. Additional in
vitro scientific evaluations have been subsequently undertaken. These
data indicate that low osmolar nonionic contrast media confers less of
an anticoagulant effect than ionic contrast media (3). Nonionic con-
trast reduces platelet surface charge, binds fibrinogen and modifies
fibrin clot formation. Ionic contrast media have been found to produce
more profound effects on fibrin fiber formation at low levels, but
similar effects are observed at typical in vivo doses. There appears to be
no inherent thrombogenicity of low osmolar nonionic contrast media.
Granger et al. (4) reported in vivo data on nonionic contrast agents
indicating that both ionic and nonionic contrast cause alteration in
fibrin assembly that may be difficult to lyse when these thrombi occur
(4).
Large-scale clinical trials on the thrombotic potential of nonionic
contrast in the setting of diagnostic cardiac catheterization have
demonstrated no increase in the incidence of major thrombotic
complications. A study of 8,517 consecutive patients undergoing
diagnostic cardiac catheterization reported the incidence of throm-
botic complications to be 0.18% (5). This figure compares favorably to
large-scale trials describing thrombotic complications with ionic con-
trast media.
The prospective trial performed by Grines et al. has several
limitations. The most important of which is recognized by the authors.
The study involved a relatively small cohort of patients, and therefore
all statistical significance levels of the prespecified end points were
either borderline or not significant. Of the three primary end points,
angiographic evidence of intermittent patency, thrombus formation or
distal embolization, only Thrombolysis in Myocardial Infarction
(TIMI) flow that decreased by one or more grade was able to achieve
borderline significance, with a p value of 0.04. Neither of the other two
primary end points were statistically significant. Similarly, for the
secondary end points of recurrent ischemia and need for revascular-
ization, neither reached statistical significance. Early reocclusion or
restenosis requiring angioplasty was only of borderline significance,
with a p value of 0.06.
Although, patients were more likely to undergo recatheterization
in the group receiving low osmolar ionic contrast, recurrent pain was
noted equally in the two groups. There was no increase in the
incidence of early reocclusion, restenosis requiring reangioplasty or
documented abrupt closure. The authors undertook several subgroup
analyses of the data that were not prespecified end points of the trial.
Using this strategy, they uncovered several univariate factors more
prevalent in a nonionic contrast group. These included symptoms of
angina, angina at rest and reduced need for subsequent bypass surgery.
If additional univariate comparisons are made, then statistical correc-
tion for multiple comparisons should be applied to these data. When
this correction is used, none of the variables are statistically significant.
Why was a multivariate analysis performed?
Of additional concern is the higher dose of maintenance heparin
infusion after precutaneous transluminal coronary angioplasty in the
group receiving low osmolar nonionic contrast medium. Recent data
suggest that heparin stimulates fibrinogen receptor activation and
alpha degranulation of platelets and may also induce immunoglobulin
G antibodies that cause platelet activation and thrombocytopenia
(6,7). Thus, the concern is the additional dose and duration of heparin
therapy in the nonionic contrast group may be an important contrib-
uting factor to the adverse events that were observed. The use of
glycoprotein IIb/IIIa inhibitors was not available during this trial but is
primarily indicated for the patient cohort that was evaluated. What
effect this potent inhibitor of platelet aggregation would have on these
results is unknown.
Although the authors should be commended for their pilot work,
additional larger scale, prospective, randomized trials will be necessary
to further evaluate this question. The preponderance of available
experimental and clinical data fail to indicate that low osmolar ionic
contrast media are the preferable agent in the setting of coronary
angioplasty.
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Reply
Davidson raises several issues in response to our randomized trial (1)
that demonstrated that ionic contrast is superior to nonionic contrast
in reducing the risk of ischemic complications after coronary angio-
plasty:
1. Davidson references his publication in which retrospective
review of patients undergoing diagnostic catheterization showed no
difference in thromboembolic complications when ionic and nonionic
agents were compared. We acknowledged this in our original discus-
sion; however, we noted that “It was an observational study limited to
patients undergoing only diagnostic catheterization, a procedure asso-
ciated with a low incidence of thromboembolic events.” Given the low
frequency of events in patients undergoing elective catheterization, a
randomized trial of tens of thousands of patients may be necessary to
show a significant difference.
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